Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07052877

The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab

This trial is a single arm study for patients receiving bevacizumab for IDH-wildtype glioblastoma. Patients receiving bevacizumab (an anti-VEGF therapy) will receive PSMA scans to investigate the role of PSMA expression in glioblastoma and its relationship to VEGF expression.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Glioblastoma Astrocytoma Glioblastoma Multiforme (GBM) Glioma Neoplasms Neoplasms by Histologic Type Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Neoplasms, Neuroepithelial Neuroectodermal Tumors

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • > 18 year of age
  • ECOG 0-2
  • Able to provide informed consent for the study
  • Minimum of 1 month from completion of radiotherapy with clinical or radiography evidence suggesting residual tumour
  • Confirmed glioblastoma IDH1/2 wildtype (WHO2021)
  • For bevacizumab treatment as per treating physician
  • Able to comply with trial requirements

Exclusion criteria

  • No major organ impairment that would likely lead to unacceptable toxicities- eg significant cardiac, hepatic, renal or haematologic dysfunction (based on clinician assessment)
  • Any contraindication to bevacizumab, MRI gadolinium contrast or 68Ga-PSMA-617 radioisotope
  • Any implant, foreign body, 3T MRI incompatible device or other contraindication to MRI imaging
  • Does not fulfill PBS requirements for bevacizumab
  • Women lactating, pregnant or of child baring potential who are not willing to avoid pregnancy during the study

Treatment and study plan

PSMA PET/CT scan

Diagnostic Test

PSMA PET scan will be used to monitor changes in PSMA expression in response to bevacizumab.

Primary outcomes

  1. Changes in PSMA PET metabolic tumour volume (MTV) before and after bevacizumab administration.

    Time frame: Prior to first administration of bevacizumab to 6 weeks after.

Other outcomes

  1. Changes in PSMA PET SUVmax before and after bevacizumab administration.

    Time frame: Prior to first administration of bevacizumab to 6 weeks after.

  2. Changes in PSMA PET SUVmean before and after bevacizumab administration.

    Time frame: Prior to first administration of bevacizumab to 6 weeks after.

  3. Changes in PSMA PET SUVpeak before and after bevacizumab administration.

    Time frame: Prior to first administration of bevacizumab to 6 weeks after.

Study contacts

Contact information is provided by the study sponsor or research team.

Alexander Yuile

CONTACT

[email protected]

+61 2 94631171

Sponsors and collaborators

Lead sponsor

Royal North Shore Hospital

Other

Registry information

Official study title

Investigating Glioblastoma PSMA Expression by Utilizing Anti-VEGF and Its Effect on PSMA PET Scan Avidity

Acronym: GUAVA

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Jul 7, 2025
Registry last updated
Jul 11, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.